Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P46098 (5-HT3 receptor)
 2,290 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CRF is produced in the Leydig cells and acts as a negative autocrine regulator of Leydig cell function. To clarify the hormonal control of CRF secretion by Leydig cells, we evaluated the participation of serotonin (5HT) and serotonin agonists in the release of CRF from Leydig cells and their effects on hCG-induced cAMP generation and steroidogenesis. Serotonin stimulated CRF secretion up to 4-fold above basal levels and inhibited basal and hCG-stimulated cAMP generation and testosterone production (ID50, 1 nM). The inhibitory action of 5HT was prevented by a CRF antibody and the alpha-helical CRF-(9-41) antagonist. The selective 5HT2 receptor agonist (+-)1-[2,5-dimethoxy-4-iodophyryl]2-amino propane hydrochloride (DOI) also stimulated CRF secretion and inhibited hCG-stimulated cAMP generation and testosterone production to control levels (ID50, 7 microM). Serotonergic 5HT1A, 5HT1B/1C, 5HT1D, and 5HT3/5HT2 agonists were less effective inhibitors of hCG-stimulated cAMP and testosterone production, while agonists for the 5HT3 receptor had no effect. [125I]DOI binding studies in Leydig cells demonstrated two sets of receptors with Kd values in the nanomolar and micromolar range, with low and high capacities, respectively. The low affinity site differed from that of brain receptors (Kd, 4.2 nM) and displayed higher binding capacity (50-fold). The selective 5HT2 receptor antagonist ketanserin prevented CRF stimulation and blocked the inhibitory actions of 5HT and DOI, while the alpha 1-adrenergic antagonist prazosin had no effect. Also, treatment of cells with ketanserin increased sensitivity to hCG and raised maximal cAMP and testosterone production. 5HT was a more effective stimulus than hCG in stimulating CRF secretion, and gonadotropin-induced CRF release was inhibited by ketanserin. Inhibitory effects of exogenous CRF were demonstrable after blockade of 5HT action by ketanserin. The inhibitory actions of 5HT were unaffected by pertussis and cholera toxins and were reversed by the addition of 8-bromo-cAMP. These results demonstrate that 5HT acts on 5HT2 receptors in Leydig cells that are distinct from those in the brain to stimulate CRF secretion through a pertussis toxin-insensitive G-protein. This action of 5HT is predominantly mediated by the low affinity 5HT2-binding site and requires full occupancy for maximal CRF stimulation, indicating the absence of spare receptors. 5HT-stimulated CRF inhibits basal and hCG-induced cAMP generation and steroidogenesis. Furthermore, 5HT mediates the stimulatory action of LH/hCG on CRF secretion from Leydig cells and, thus, participates in a negative autoregulatory loop to limit the testosterone response to the gonadotropic stimulus.
 ...
PMID:Regulation of corticotropin-releasing factor secretion from Leydig cells by serotonin. 131 25

1. The behavioural effects of classical anxiolytics such as barbiturates and benzodiazepines have been well characterised. However, recent research has been aimed at the development of novel anxiolytics without problems of sedation, muscle relaxation, amnesia and dependence. 2. A number of novel omega (benzodiazepine) receptor ligands with anxiolytic properties have been described including alpidem, bretazenil, suriclone and abecarnil. Although these compounds share some behavioural effects with older anxiolytic drugs, such as increasing punished drinking, they also show many differences. Their novel profiles may be related to low intrinsic activity or to selectivity for omega receptor subtypes. 3. The possibility that novel anxiolytics may be found among compounds active at serotonin receptors remains a strong hypothesis. Compounds, which, like buspirone, are active at 5HT1A receptors may be anxiolytic as may be antagonists at 5HT2 and 5HT3 receptors. All these compounds have behavioural effects which differ from those of benzodiazepines. 4. In order more effectively to screen for and develop novel anxiolytics it will be necessary to refine behavioural models in the light of feedback from the clinic.
 ...
PMID:Animal models of anxiety and the development of novel anxiolytic drugs. 167 41

5HT has been implicated in mechanisms of anxiety and depression for many years but the evidence is contradictory. Perhaps one error has been to think of 5HT as a unitary system when in reality it is highly differentiated. There has been an explosive increase in knowledge about different 5HT receptor subtypes and it has long been known that there are different anatomical subsystems. Evidence will be summarised that the different systems subserve different psychological functions and that dysfunction in the different systems results in depression, anxiety, panic and OCD in an understandable way. Much evidence is compatible with the idea that 5HT systems reduce the impact of impending or actual aversive events. Anticipation of an aversive event is associated with anxiety and this motivates avoidance behaviour--a normal adaptive response. There is evidence that this is mediated by projections of the dorsal raphe nucleus and associated 5HT2 and 5HT3 receptors. Projections of the median raphe nucleus and associated 5HT1A receptors appear to mediate resilience to aversive events once they have occurred or if they persist. When this system breaks down depression results. It will be argued that all effective antidepressants act on 5HT1A, natural mechanisms of resilience.
 ...
PMID:Depression and 5HT. 180 32

We have previously reported that serotonin (5-hydroxytryptamine [5HT]) alters cultured bovine pulmonary artery smooth muscle cell (SMC) configuration through two different regulatory mechanisms. We now report that 5HT also regulates SMC growth through these same two mechanisms--a stimulatory event initiated intracellularly and inhibition of growth resulting from a cell surface action. 5HT (1 microM) plus 0.1 mM iproniazid (a 5HT metabolic inhibitor) produced a severalfold stimulation of DNA synthesis (as measured by [3H]thymidine incorporation) of SMCs after a 17-24-hour incubation with only a slight elevation of cellular cAMP. This stimulatory effect responded synergistically with other growth factors including platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor and was effectively reversed by 5HT uptake inhibition. It was not produced by 5-hydroxyindoleacetic acid, a metabolite of 5HT. In the presence of 1 microM 5HT plus 0.1 mM isobutylmethylxanthine (IBMX), cAMP was elevated eightfold, dendritic formation occurred, and [3H]thymidine labeling of SMCs was inhibited. Inhibition of labeling by [3H]thymidine was mimicked by other agents that elevated cellular cAMP (10 microM histamine, 1 microM isoproterenol plus 0.1 mM IBMX, and 10 microM forskolin) and by 1 mM dibutyryl cAMP. This inhibitory effect was not blocked by either inhibition of 5HT uptake or 5HT-receptor antagonists ketanserin (5HT2); methiothepin, spiperone, and mianserin (5HT1/5HT2); and 3-tropanyl-indole-3-carboxylate and 3-tropanyl-3,5-dichlorobenzoate (5HT3). However, similar to 5HT, the 5HT1A agonist, (+/-)-8-hydroxy-(+/-)-2-dipropylamino-8-hydroxy-1,2,3, 4-tetrahydronaphthalenehydrobromide, in association with IBMX, produced an elevation in cAMP and inhibition of labeling by [3H]thymidine. 5HT, in the presence of either iproniazid or IBMX, did not alter [Ca2+]i, indicating that [Ca2+]i was not a signal for either of these actions.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. 185 Mar 32

Serotonin is a biogenic amine that can exert multiple effects on smooth muscle, including smooth muscle of the genitourinary tract; effects that may be species dependent. The present study using isolated tissues documents potent contractile responses to serotonin in canine bladder smooth muscle. Contractile responses to serotonin in canine bladder could be mimicked by alpha-methyl serotonin, a selective 5HT2 receptor agonist. In fact, although alpha-methyl serotonin was slightly less potent as a contractile agonist relative to serotonin, the contractile response to alpha-methyl serotonin was more persistent as evidenced by a greater recovery time to resting force following washout. In contrast, the 5HT1A receptor agonist, 8-OH-DPAT and the 5HT3 selective agonist, 2-methyl serotonin, did not markedly contract canine bladder. These data establish that contractile responses to serotonin in the canine bladder are mediated by activation of 5HT2 receptors. We further demonstrated that the 5HT2 receptor antagonist, LY53857, potently inhibited the contractile response to both serotonin and alpha-methyl serotonin in the canine bladder consistent with agonist activation of 5HT2 receptors. In contrast to the potent response to serotonin observed in the canine bladder, rat bladder preparations did not markedly contract in response to serotonin, alpha-methyl serotonin, 8-OH-DPAT, or 2-methyl serotonin. Thus, these studies reinforce the marked species variability in responsiveness to serotonin and indicate that contraction to serotonin in the canine bladder is mediated by activation of the 5HT2 receptor.
 ...
PMID:Canine, but not rat bladder contracts to serotonin via activation of 5HT2 receptors. 213 74

The receptor mediating contraction in response to serotonin in the rat stomach fundus has not been characterized in light of the currently acceptable serotonergic receptor classification scheme. Several biochemical and pharmacological approaches to a characterization of this receptor have demonstrated nonidentity with the 5-hydroxytryptamine2 (5HT2), 5HT3, 5HT1A, and 5HT1B receptors, as defined by radiolabeled ligand binding studies in brain cortical membranes. Although there have been reports suggesting that the receptor in the rat stomach fundus may be analogous to the 5HT1C receptor, other pharmacological and biochemical studies have not been consistent with this idea. The present study utilized high affinity ligands for the 5HT1C receptor and the recently derived 5HT1C receptor cDNA clone to provide a more definitive approach to the examination of the relationship between the 5HT1C receptor and the serotonergic contractile receptor in the rat stomach fundus. Using three ligands with high affinity at the 5HT1C receptor, LY53857, ritanserin, and SCH23390, the contractile response to serotonin was inhibited by all three ligands. However, inhibition did not appear competitive nor was the inhibitory potency of these ligands consistent with their affinity at 5HT1C binding sites in brain cortical membranes. We further showed that SCH23390, unlike LY53857 and ritanserin, was also a partial agonist, producing a maximal contraction that was approximately 50% of the maximal response to serotonin in the rat stomach fundus. Thus, the use of these ligands did not support the contention that the receptor mediating serotonin-induced contractions in the rat stomach is identical to the 5HT1C receptor. In more definitive studies using a 5HT1C receptor cDNA probe, we were unable to detect hybridization of the probe with any mRNA species from the rat stomach fundus, whereas the 5HT1C receptor cDNA probe did hybridize to the 5HT1C receptor mRNA in rat brain. Because the cathepsin-D cDNA probe hybridized equally in rat brain and stomach fundus, ensuring the integrity of the RNA preparation from both tissues, the absence of measurable quantities of the 5HT1C receptor mRNA in the rat stomach was probe specific and not an artifact. Furthermore, primers specific for the rat 5HT1C receptor sequence did not detect significant levels of receptor mRNA in rat fundus, although the target sequence was amplified a minimum of 10(5)-fold in a polymerase chain reaction. These studies do not support the contention that the receptor mediating contractile responses to serotonin in the rat stomach fundus is identical to the 5HT1C receptor.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Pharmacological and molecular evidence that the contractile response to serotonin in rat stomach fundus is not mediated by activation of the 5-hydroxytryptamine1C receptor. 219 36

Radioligand binding studies were performed to characterize serotonin 5HT1D binding sites in porcine and bovine brain. 3H-5HT binding, in the presence of 1 microM (+/-)pindolol (to block 5HT1A and 5HT1B receptors) and 100 nM mesulergine (to block 5HT1C receptors), was specific, saturable, and of high affinity. In porcine and bovine cortex and striatum the majority of 5HT1 sites (80%-90%) were of the 5HT1D subtype. In competition experiments 8-OH-DPAT, TFMPP, mesulergine, DOB, and ICS 205-930 had low affinity for 3H-5HT-labeled 5HT1D sites, indicating that the pharmacology of the 5HT1D site is distinct from previously identified 5HT1A, 5HT1B, 5HT1C, 5HT2, and 5HT3 sites. Guanyl nucleotides, GTPgammaS, and Gpp(NH)p, and divalent cations potently modulated the binding of 3H-5HT to 5HT1D sites in porcine and bovine striatum. Mg++ ions increased the number and affinity of 3H-5HT-labeled 5HT1D sites, while guanyl nucleotides decreased the number of 3H-5HT-labeled 5HT1D sites. These results demonstrate the presence of the 5HT1D receptors in porcine striatum and bovine cortex and provide direct demonstration that the radioligand binding assay for the 5HT1D receptor can monitor the interaction of this receptor with a GTP-binding protein.
 ...
PMID:Detection and characterization of a 5HT1D serotonin receptor-GTP binding protein interaction in porcine and bovine brain. 252 22

1. It has been long suggested that central 5HT-mediated systems may be involved in modulation of anxiety and in the anxiolytic effect of benzodiazepines. However, recent evidence has questioned this hypothesis, particularly with respect to the mode of action of benzodiazepines. 2. Development of 5HT agonists and antagonists selective for different 5HT receptor sub-types (5HT1A, 5HT1B, 5HT2, 5HT3) has opened a new avenue for investigation of the potential role of 5HT in anxiety. 3. Buspirone is clinically active in the treatment of anxiety and it, and other anxiolytic candidates, gepirone and isapirone, may act as agonists (or perhaps partial agonists) on 5HT1A receptors. 4. The prototype 5HT1A agonist 8OH-DPAT may also have potential anxiolytic effects. 5HT1A agonists may act to suppress the activity of 5HT neurones as a major part of their action. 5. Although there is some supporting evidence, there is no clear indication of anxiolytic activity with agonists with some selectivity for 5HT1B sites (RU24969, mCPP, TMPP). 6. A selective 5HT2 antagonist, ritanserin, has anxiolytic effects in clinical studies but, like the 5HT1A agonists, does not show a similar profile to benzodiazepines in models of anxiety. 7. This raises the question of clinical predictivity of the various models used. 8. A recently developed 5HT3 antagonist, GR38032F, has been claimed to possess potential anxiolytic activity but its mode of action in this respect requires further elucidation.
 ...
PMID:Potential use of drugs modulating 5HT activity in the treatment of anxiety. 290 81

The isolated perfused guinea pig lung was used to investigate pharmacologic characteristics of serotonin receptors in pulmonary vascular and airway smooth muscle. Serotonin caused a marked dose-related increase in pulmonary arterial pressure and peak intratracheal pressure when injected into the pulmonary artery. In contrast to serotonin, 5-carboxamidotryptamine, a 5HT1A and 5HT1B receptor agonist, and 2-methylserotonin, a 5HT3 receptor agonist produced only weak vascular and airway responses. Furthermore, vasoconstriction and bronchoconstriction elicited by serotonin were antagonized by the potent 5HT2 receptor antagonists, LY53857, ketanserin, and ritanserin. Antagonist specificity for 5HT2 receptors was demonstrated in the perfused guinea pig lung since similar responses induced by histamine were not blocked. High concentrations of serotonin were tachyphylactic on vascular but not airway constriction. Tachyphylaxis of vascular responses was not observed to an equipotent concentration of leukotriene D4 (LTD4). Thus, both the pulmonary vascular and airway constriction to serotonin were predominantly due to 5HT2 receptor activation. Furthermore, tachyphylaxis of vascular responses to serotonin might prove useful to differentiate 5HT receptor systems in pulmonary blood vessels from those in airways.
 ...
PMID:Serotonin-induced pulmonary responses in the perfused guinea pig lung: evidence for 5HT2 receptor-mediated pulmonary vascular and airway smooth muscle constriction. 298 Feb 93

Serotonin (5HT) is a potent agonist in contracting the rat stomach fundus although the nature of the receptor mediating the response has not been established. The present study was designed to explore the possibility that 5HT-induced contractions in the rat stomach fundus were mediated by interaction with receptors identical with either 5HT1A, 5HT1B or 5HT1C binding sites or 5HT3 receptors. Contractile concentration-response curves for several 5HT agonists [5-carboxamidotryptamine, TR3369, MK212, quipazine, RU 24969, 8-hydroxy-2-(di-n-propylamino)tetralin, TVXQ7821 and BEA 1654CL] were obtained in the rat stomach fundus. However, neither the potency nor maximum response of these agonists in contracting the rat stomach fundus correlated with the affinity of agonists at 5HT1A, 5Ht1B or 5HT1C binding sites. These agonists were interacting with 5HT receptors in the fundus based on the ability of 1-(1-naphthyl) piperazine (10(-7) M) to antagonize the contractile response of the relatively potent agonists. TVXQ7821 and BEA 1654Cl did not produce a marked contractile response in the fundus and also did not antagonize the contractile response to 5HT, suggesting that these agents have little, if any, affinity for the serotonergic receptor-mediating contraction in the fundus. The putative 5HT1A-selective receptor antagonists, WB4101 and spiroxatrine, did not block 5HT-induced contractions in the rat stomach fundus in concentrations consistent with their affinity at 5HT1A binding sites. The nonselective 5HT1A and 5HT1B receptor antagonist, cyanopindolol, also did not block 5HT-induced contractions in the rat stomach fundus.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Contractile serotonergic receptor in rat stomach fundus. 366 56


1 2 3 Next >>